LLY is trading at $1103.03 (+3.7%) amid reports of advanced talks to acquire Ventyx Biosciences for over $1 billion.
- Ventyx's experimental pills target obesity-related cardiovascular disease, Crohn's, rheumatoid arthritis, and Parkinson's, bolstering Lilly's portfolios in autoimmune, obesity, and neurodegeneration.
- The move coincides with Novo Nordisk's oral Wegovy launch, outpacing the flat broader market.
- Analyst projections suggest Lilly could hit $94.3B in revenue by 2027, adding significant tailwinds.